Forsta Ap Fonden Bei Gene, Ltd. Transaction History

Forsta Ap Fonden

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 09, 2021	SELL	$221.31 - $316.61 $1.59 Million - $2.28 Million	-7,200 Closed	0 $0
Q3 2020 Oct 22, 2020	BUY	$189.18 - $286.44 $454,032 - $687,456	2,400 Added 50.0%	7,200 $2.06 Million
Q2 2020 Aug 11, 2020	BUY	$123.9 - $195.41 $99,120 - $156,328	800 Added 20.0%	4,800 $904,000
Q1 2020 May 04, 2020	BUY	$121.84 - $173.19 $219,312 - $311,742	1,800 Added 81.82%	4,000 $492,000
Q4 2019 Feb 12, 2020	BUY	$115.78 - $208.34 $254,716 - $458,348	2,200 New	2,200 $365,000

216

45.1M

76.5K

72.3K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $14.8B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Forsta Ap Fonden, based on Form 13F filings with the SEC.

Stay updated on Forsta Ap Fonden with notifications on news.